Safety Consequences of Off-Label Drugs Used for COVID-19. | Drug Saf;44(4): 399-402, 2021 04. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Safety Consequences of Off-Label Drugs Used for COVID-19.

Dasgupta, Nabarun.

Dasgupta N; Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. nab@unc.edu.

Drug Saf ; 44(4): 399-402, 2021 04.

Article in English | MEDLINE | ID: covidwho-1157034

Subject(s)

COVID-19; Pharmaceutical Preparations; Drug Utilization; Humans; Off-Label Use; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmaceutical Preparations / COVID-19 Limits: Humans Language: English Journal: Drug Saf Journal subject: Drug Therapy / Toxicology Year: 2021 Document Type: Article Affiliation country: S40264-021-01056-0

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmaceutical Preparations / COVID-19 Limits: Humans Language: English Journal: Drug Saf Journal subject: Drug Therapy / Toxicology Year: 2021 Document Type: Article Affiliation country: S40264-021-01056-0